Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1SLC9A3
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.67 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.46 |
| ▸ | LAP3 | P28838 | 2/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.37 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.37 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL15005520 | 1.00 | SLC7A5 (0.67) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL165422 | 0.96 | SLC7A5 (0.72) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL15005636 | 0.89 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL446832 | 0.88 | SLC7A5 (0.86) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL29269093 | 0.86 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL16651962 | 0.86 | SLC7A5 (0.90) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL29204313 | 0.84 | SLC7A5 (0.86) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL29805351 | 0.84 | SLC7A5 (0.95) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| Leucine SCHEMBL16588898 | 0.82 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 | |
| Leucine SCHEMBL23632641 | 0.82 | SLC7A5 (0.90) | SLC7A5SLC1A3SLC1A2SLC1A1LAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150202227-A1 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE | PULMATRIX, INC. | 2015-07-23 | — | — | US | disclosed |
| US-8992983-B2 | Respirably dry powder comprising calcium lactate, sodium chloride and leucine | PULMATRIX, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150004233-A1 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE | PULMATRIX, INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-8758824-B2 | Respirably dry powder comprising calcium lactate, sodium chloride and leucine | PULMATRIX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130164338-A1 | TREATMENT OF CYSTIC FIBROSIS USING CALCIUM LACTATE, LEUCINE AND SODIUM CHLORIDE IN A RESPIRAPLE DRY POWDER | PULMATRIX, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130149345-A1 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE | PULMATRIX INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2448571-B1 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE | PULMATRIX INC (US) | 2013-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149345-A1 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE | LDHA, LDHB, LCT | SLC7A5 245/4885SLC1A3 753/4885SLC1A2 778/4885 |
| US-20150004233-A1 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE | LDHA, LDHB, CLCN2 | SLC7A5 218/4885SLC1A3 639/4885SLC1A2 604/4885 |
| US-20150202227-A1 | RESPIRABLY DRY POWDER COMPRISING CALCIUM LACTATE, SODIUM CHLORIDE AND LEUCINE | LDHA, LDHB, CLCN2 | SLC7A5 313/4885SLC1A3 572/4885SLC1A2 565/4885 |
| US-20130164338-A1 | TREATMENT OF CYSTIC FIBROSIS USING CALCIUM LACTATE, LEUCINE AND SODIUM CHLORIDE IN A RESPIRAPLE DRY POWDER | CLCN2, CFTR, CA2 | SLC7A5 191/4885SLC1A3 320/4885SLC1A2 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.